Simplified 14-day trifluridine-tipiracil schedule shows non-inferior survival in refractory metastatic colorectal cancer

▸ TREATMENT

The phase III PRABITAS trial in Japan randomized 970 patients and found that a 14-day schedule of trifluridine-tipiracil plus bevacizumab was non-inferior to the conventional 28-day schedule for overall survival, potentially reducing treatment-related toxicity. (The Lancet)